secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001140361-25-030701
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech reports Q2 net loss $9.4M, clinical updates on PDS0101 and PDS01ADC
-------------------------------------------------------------------------------

- Net loss $9.4M ($0.21/dil share) vs $8.3M ($0.23) in Q2 2024.
- R&D $4.2M, G&A $3.4M; total operating expenses $7.6M vs $8.7M.
- Cash $31.9M (6/30/25) vs $41.7M (12/31/24); net interest expense $1.8M vs $0.5M.
- Colorectal cancer cohort of Phase 2 trial with PDS01ADC met expansion criteria (≥6 of 9 objective responses).
- Phase 3 VERSATILE-003 trial for PDS0101 in HPV16+ HNSCC progressing; 3 ASCO 2025 abstracts presented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125030701/0001140361-25-030701-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125030701/ef20053853_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-030701

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer